<DOC>
	<DOCNO>NCT01274351</DOCNO>
	<brief_summary>This study design investigate molecular cytogenetic effect safety profile nilotinib treatment early chronic phase Ph+ CML among different risk group patient compare patient high Socal risk score patient intermediate low Socal risk score .</brief_summary>
	<brief_title>Study Nilotinib First Line Treatment Philadelphia Chromosome Positive ( Ph+ ) Chronic Myelogenous Leukemia Chronic Phase ( CML-CP )</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Philadelphia Chromosome</mesh_term>
	<criteria>Eastern Cooperative Oncology Group ( ECOG ) performance status 0 , 1 , 2 First cytogenetic diagnosis CMLCP cytogenetic confirmation Philadelphia chromosome ( 9 ; 22 ) translocation within 6 month . Standard conventional cytogenetic analysis must perform . Previously untreated CML , except hydroxyurea and/or anagrelide ( except imatinib treatment max . 31 day long ) Adequate end organ function follow laboratory criterion : total bilirubin &lt; 1.5 x upper limit normal ( ULN ) ; alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) &lt; 2.5 x upper limit normal ( ULN ) ; creatinine &lt; 1.5 x upper limit normal ( ULN ) ; serum amylase lipase ≤ 1.5 x upper limit normal ( ULN ) ; alkaline phosphatase ≤ 2.5 x upper limit normal ( ULN ) unless consider tumor related Serum potassium , magnesium , phosphorus level equal low limit normal prior first dose study medication Treatment tyrosine kinase inhibitor ( ) prior study ( emergent case patient require disease management await study start , commercial supply imatinib dose may prescribe patient longer 31 day duration ) Known cytopathologically confirm Central Nervous System CNS infiltration Impaired cardiac function Severe uncontrolled medical condition ( i.e . uncontrolled diabetes , active uncontrolled infection ) Acute chronic liver , pancreatic severe renal disease consider unrelated disease Patients another primary malignancy except primary malignancy neither currently clinically significant require active intervention History significant congenital acquire bleed disorder unrelated cancer Previous radiotherapy ≥25 % bone marrow Impairment gastrointestinal ( GI ) function GI disease may significantly alter absorption study drug ( e.g. , ulcerative disease , uncontrolled nausea , vomit , diarrhea , malabsorption syndrome , small bowel resection , gastric bypass surgery ) Use therapeutic coumarin derivative ( i.e . warfarin , acenocoumarol , phenprocoumon ) Patients actively receiving therapy strong Cytochrome P450 3A4 isoenzyme ( CYP3A4 ) inhibitor ( e.g , erythromycin , ketoconazole , itraconazole , voriconazole , clarithromycin , telithromycin , ritonavir , mibefradil ) Patients actively receiving therapy medication potential prolong QT interval treatment either discontinue switched different medication prior start study drug Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>First line treatment</keyword>
	<keyword>newly diagnose</keyword>
	<keyword>Philadelphia chromosome positive</keyword>
	<keyword>Chronic Myelogenous Leukemia</keyword>
	<keyword>Ph+</keyword>
	<keyword>CML-CP</keyword>
	<keyword>major molecular response</keyword>
	<keyword>Social risk</keyword>
</DOC>